Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s price target indicates a potential upside of 465.61% from the company’s previous close.

HUMA has been the subject of a number of other reports. TD Cowen restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. Finally, Benchmark upped their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Up 0.2 %

Shares of NASDAQ:HUMA traded up $0.01 on Tuesday, hitting $4.42. The company had a trading volume of 261,992 shares, compared to its average volume of 2,998,319. The business has a 50 day moving average of $4.55 and a 200 day moving average of $5.65. The company has a market cap of $556.30 million, a PE ratio of -3.36 and a beta of 1.32. Humacyte has a 52-week low of $2.69 and a 52-week high of $9.97.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. This represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Large investors have recently added to or reduced their stakes in the stock. Brookstone Capital Management acquired a new position in shares of Humacyte during the 4th quarter worth about $56,000. ACT Wealth Management LLC acquired a new position in shares of Humacyte during the fourth quarter worth approximately $57,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the third quarter valued at approximately $75,000. FORA Capital LLC acquired a new stake in shares of Humacyte in the third quarter worth $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte in the second quarter worth $97,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.